Navigation Links
Sigma-Tau Pharmaceuticals and Danisco BioActives Announce Partnership Agreement to Develop Drug Candidate for Prevention of Necrotizing Enterocolitis
Date:4/7/2009

erocolitis (NEC)

NEC is a life-threatening gastrointestinal disorder with significant morbidity and mortality primarily affecting premature infants under 1500 grams, known as very low birth weight infants. Every year, thousands of premature babies die as a result of this disease and more will suffer from abnormal neurodevelopmental outcomes. While the cause of the disease is unknown, the pathological findings of infants who died of NEC show intense mucosal inflammation, hemorrhage and transmural necrosis of the small and large intestines.

In the United States, more than 300,000 premature babies (less than 2500 grams) are born each year. Of this group, the 60,000 to 70,000 that weigh less than 1,500 grams at birth are at high risk for acquiring NEC.

About Sigma-Tau Pharmaceuticals, Inc.

Sigma-Tau Pharmaceuticals, Inc. is a U.S. based, wholly owned subsidiary of the Sigma-Tau Group, and is dedicated solely to the global development and commercialization of medicines for patients with rare diseases. Sigma-Tau Pharmaceuticals, Inc. is based in Gaithersburg, Maryland.

Since 1989, the company's products have been focused on rare diseases, kidney disease, and cancer. With more than 6,000 identified rare diseases that affect approximately 25 million patients in the United States, Sigma-Tau places its considerable scientific resources behind the development and commercialization of compounds that benefit the few. The company has substantial development programs focused on transplant, cancer, inherited genetic disorders, malaria, and other areas of unmet medical need.

For more information about the company, visit www.sigmatau.com.

About Danisco

With a rich and innovative portfolio, Danisco is a world leader in food ingredients, enzymes and bio-based solutio
'/>"/>

SOURCE Sigma-Tau Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Anesiva and Sigma-Tau Announce Exclusive Marketing and Distribution Agreement for Zingo(TM) in Six European Countries
2. DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease
3. Sigma-tau HealthScience Launches www.GlycoCarn.com
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2015)... 2015 “ ActOn ” was featured on ... look at the latest and coolest applications on the market ... AppWatch and technology expert, conducted the app review and shared ... with organizations to make a difference. , In this material ... things that aren’t about money, which is why those things ...
(Date:5/2/2015)... “ Peachtree Audio ” was featured ... which features the latest and coolest technology products available ... reporter for NewsWatch, conducted the review and shared with ... , Music is an important part of people’s lives ... given the royal treatment. Peachtree Audio does just that ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 ZoomCare, the ... has submitted plans to offer its new healthcare insurance ... The ZOOM+ Personal Health Insurance System is the nation’s ... to enhance human performance. ZOOM+ Personal Health Insurance was ... delivery system that are subject to review and regulation ...
(Date:5/1/2015)... 2015 Pioneer Millworks, the largest reclaimed ... in their reclaimed wood products at the 27th annual ... Center in NYC this May. Their newest offerings, Vat ... anticipated texture and color to North America's platform for ... texture and color in the design world and we're ...
(Date:5/1/2015)... (PRWEB) May 01, 2015 TROY Healthcare ... Cerner Southeast Regional User Group (RUG) Conference in Atlanta, ... Southeast Regional User Group Conference provides a forum for ... who support all aspects of electronic medical record operations, ... Cerner software applications. , In addition to sponsoring the ...
Breaking Medicine News(10 mins):Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 3Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 3
... By Steven Reinberg HealthDay Reporter , THURSDAY, ... Administration has announced that the controversial diabetes drug Avandia will ... due to the cardiovascular risks it poses to patients. ... on Nov. 18, the medication will only be available to ...
... University of Louisville, UCLA and the California Institute of Technology ... a paralyzed male volunteer at Louisville,s Frazier Rehab Institute. It ... potential clinical therapies for paralysis. The study is ... The man, Rob Summers, age 25, was completely ...
... , THURSDAY, May 19 (HealthDay News) -- When ... items and use a credit card when they make those ... volunteers completed a meaningless computer test, and then some of ... test, suggesting they weren,t very smart, while others were told ...
... human ability to stand on two legs may have developed because ... University of Utah researchers used a punching bag fitted with a ... martial arts experts as they hit the bag in four different ... from a standing position and while on their hands and knees. ...
... cancer patients with defects in mismatch repair--one of the ... and better survival rates than patients without such defects, ... the Journal of the National Cancer Institute. ... mismatch repair defects. Some defects are caused by the ...
... May 19, 2011 The Children,s Health Insurance Program ... recommended health care quality measures to be identified for ... Insurance Programs (CHIP), which together cover almost 40 million ... Academic Pediatrics, the official journal of the American Pediatric ...
Cached Medicine News:Health News:FDA to Pull Diabetes Drug Avandia From Pharmacy Shelves 2Health News:FDA to Pull Diabetes Drug Avandia From Pharmacy Shelves 3Health News:Paraplegic man stands, steps with assistance and moves his legs voluntarily 2Health News:Paraplegic man stands, steps with assistance and moves his legs voluntarily 3Health News:Paraplegic man stands, steps with assistance and moves his legs voluntarily 4Health News:Buying Luxury Items on Credit May Be Ego Booster 2Health News:Punches Land Harder When Delivered From Above: Study 2Health News:DNA repair system affects colon cancer recurrence and survival 2Health News:Important info about CHIPRA core set of recommended health care quality measures released 2Health News:Important info about CHIPRA core set of recommended health care quality measures released 3Health News:Important info about CHIPRA core set of recommended health care quality measures released 4Health News:Important info about CHIPRA core set of recommended health care quality measures released 5
(Date:4/30/2015)... CITY, Calif., April 30, 2015 Abaxis, Inc. ... point-of-care blood analysis systems, today reported financial results for ... 2015. Fourth quarter and fiscal 2015 overview: ... for the fourth quarter, up 33% over last year,s ... 25% year-over-year. , Diluted EPS of $0.50 for ...
(Date:4/30/2015)... 2015  Tandem Diabetes Care ® , Inc. (NASDAQ: ... t:slim ® and t:flex™ Insulin Pumps, today reported its ... In comparing the first quarter of 2015 to ... percent to $12.3 million from $8.1 million , t:slim ... pumps "Our investment in resources to build the ...
(Date:4/30/2015)... 30, 2015  DURECT Corporation (Nasdaq: DRRX ) ... 2015.  Total revenues were $4.8 million and net loss ... 31, 2015 as compared to total revenues of $6.3 ... three months ended March 31, 2014.At March 31, 2015, ... to cash and investments of $34.9 million at December ...
Breaking Medicine Technology:Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 3Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 4Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 5Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 6Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 7Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 8Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 9Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 10Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 12Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 13Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 14Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 15Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 16Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 17Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 18Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 19Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 20Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 21Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 22Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 23Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 24Tandem Diabetes Care Reports First Quarter 2015 Financial Results 2Tandem Diabetes Care Reports First Quarter 2015 Financial Results 3Tandem Diabetes Care Reports First Quarter 2015 Financial Results 4Tandem Diabetes Care Reports First Quarter 2015 Financial Results 5Tandem Diabetes Care Reports First Quarter 2015 Financial Results 6DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 8
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Unipolar Ventricular Lead...
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The Vitatron Brilliant S+ lead series are endocardial leads designed for the Vitatron VDD pacemaker systems offering optimal atrial sensing, superior handling and excellent pacing characteristics....
Medicine Products: